• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169651 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
+ _: T! V! E! I* P* E
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
1 X: ?/ t/ s: N" {, n" v
% C. U; l/ F6 P( C- Y, N- f* l" y; T$ q1 E, }- Y
Sub-category:' M) l% @9 K/ A  D3 `8 i+ h( _! [3 j+ [
Molecular Targets , J2 }: d& Z9 _$ f0 e, X! f" \
( t$ f) _3 s& A' Z
5 |$ W2 H  C4 o1 y- @7 B5 o) W1 D
Category:
; y0 A" w/ k4 W2 F) \1 {" B- ITumor Biology ! g0 i, e$ F5 `- Z' f' I0 j5 w

: f: h/ X: V) u2 w) |4 [, ]' A' \8 y/ Z/ v) }% D$ l
Meeting:
( K8 n$ R* _% _$ P- N4 ]2011 ASCO Annual Meeting
4 C& @3 X$ z* E" O
* v) ~8 q3 P# @" R8 ?5 a: I5 v0 r' x2 c  D8 w# M
Session Type and Session Title:+ |3 V  V2 Y! J- o' _
Poster Discussion Session, Tumor Biology 6 b; t( \9 k# D1 x' Q% t
" i0 ]& D$ }+ n7 C

9 r1 v9 a& y' i* ]3 ?! pAbstract No:
3 E9 _4 A) ^& T0 `3 Y* s5 F* u10517
! b! C* ?( G" P7 D& g. f) G, v, A" B( Y5 [' A9 ?/ y! O/ Y

! I1 Z5 a  k- R& cCitation:3 n! x+ O% Y' r6 J, @
J Clin Oncol 29: 2011 (suppl; abstr 10517) ; u" P0 _. n% U1 w( |! e
6 A, a, L, ]: [, |. Z; X  |3 I

6 l* N1 S# I$ k. H. UAuthor(s):* r% \1 }+ M( t) Y- B2 c4 b& q1 e
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 7 i, X! N& Q9 m* U7 m# I+ A* o
- \) G" A- }& s3 U) ]" r
/ m+ ?& K+ r  k; V. W4 S

* c5 X0 Y9 R# c- o1 xAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
( S1 J5 |7 M  O+ R% ]% A% \; I" T
5 s2 a( E9 h/ r& y- P5 [" MAbstract Disclosures
* U4 w4 {' _( m; N5 e. V7 y2 i5 [8 U1 m$ M4 V1 f1 w4 {0 s4 I9 d
Abstract:
" v' U* |$ S- k- ?! l
; ?9 n/ X2 r: G  G+ J: C" N$ ~( T. g$ r( [' R' n- }
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.) Z- V+ }! m3 W8 ~- t& b6 t
! @3 ]3 G: a- x" l4 f  L& R9 u! G; p
3 f1 e$ l- A' c- Q+ ~
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 # ]  V9 m$ n: I/ K
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
6 P$ V, ^' q# ?: J: v' ~" _
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
# J+ B! M; P5 G! `+ K易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。9 G) U! M* J6 G. c8 L
ALK一个指标医院要900多 ...
& B$ H4 e, Z8 P5 |) a
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?; R$ ]( {+ d9 M

) J; q5 W+ M. V7 E1 A; P1 f3 n/ A现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表